Sharemaestro Newsreel

Alumis (NASDAQ:ALMS) Shares Gap Down After Earnings Miss

Alumis Inc. (NASDAQ:ALMS) experienced a significant share price drop after reporting disappointing earnings, missing both revenue and EPS consensus estimates. Despite the poor financial results and insider selling, analyst sentiment remains largely positive with a "Moderate Buy" consensus rating and a target price of …

Celcuity (NASDAQ:CELC) Shares Gap Down on Disappointing Earnings

U.S. Stock Futures Mixed, Heads for a Winning Week

Wall Street is headed for a winning week in which the S&P 500 has recorded a new all-time high. The Department of Commerce reported that retail sales decreased 0.6% in July. The Zacks Consensus Estimate was for a breakeven. The metric for June was …

DFTX News Today | Why did Definium Therapeutics stock go down today?

Is Phase III Rezpegaldesleukin And Cash Runway Progress Altering The Investment Case For Nektar Therapeutics (NKTR)?

Capricor Therapeutics (CAPR) Stock Surges on FDA Application Ame

Brokers Offer Predictions for RAPP Q1 Earnings

Sirenia Capital discloses 5.0% AnaptysBio (ANAB) ownership in Schedule 13G/A

Sirenia Capital Management LP and Alex Silverstein have reported a beneficial ownership of 5.0% in AnaptysBio, Inc. (ANAB) common stock, as detailed in a Schedule 13G/A filing. This stake amounts to 1,491,959 shares, based on 29,608,481 shares outstanding as of June 22, 2026. The …

HC Wainwright Issues Negative Forecast for Immunome Earnings

Mizuho raises Belite Bio stock price target to $220 on NDA progress

Evaxion (NASDAQ: EVAX) sets August 20 call for Q2 2026 results and update

RTW Investments discloses 8.3% Kailera Therapeutics (KLRA) stake on Schedule 13G

RTW Investments, LP and Roderick Wong, M.D. have reported an 8.3% beneficial ownership stake in Kailera Therapeutics, Inc. (KLRA) through a Schedule 13G filing. This amounts to 10,776,820 shares of common stock, based on 129,565,608 shares outstanding as of May 20, 2026. Both reporting …

Evaxion to announce business update and second quarter 2026 financial results on August 20, 2026

Evaxion COPENHAGEN, Denmark, August 14, 2026 - Evaxion A/S (NASDAQ: EVAX) ("Evaxion"), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, will provide a business update and report its second quarter 2026 financial results on Thursday August 20, 2026, before opening …

Kymera Therapeutics Stock 8-Day Winning Spree: Stock Climbs 14%

Handelsbanken Fonder AB Purchases Shares of 160,900 Oruka Therapeutics, Inc. $ORKA

Ligand Pharmaceuticals (LGND) Stock Trades Below Fair Value Following A 337% Run

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Ligand Pharmaceuticals stock has surged over the past five years, yet the valuation signals are split, with a Discounted Cash Flow (DCF) intrinsic value estimate …

Polar Capital discloses 5.28% Arcutis Biotherapeutics (ARQT) ownership in Schedule 13G

Polar Capital Holdings Plc and Polar Capital LLP have disclosed a 5.28% ownership stake in Arcutis Biotherapeutics, Inc. (ARQT) through a Schedule 13G filing. The investment firm beneficially owns 6,606,945 shares, with sole voting and dispositive power, based on Arcutis's 125,083,374 outstanding shares as …

Ionis Stock Has Plunged 30%. Is It Time to Buy the Beaten-Down Stock?

Key Points Q2 revenue fell, but last year included a large one-time payment. There were other signs of trouble in the earnings report. Wall Street is still bullish on the shares.10 stocks we like better than Ionis Pharmaceuticals › Shares of Ionis Pharmaceuticals(NASDAQ: IONS) …

Bernstein Adjusts PT on Regeneron Pharmaceuticals to $756 From $753, Maintains Market Perform Rating

Bernstein has increased its price target for Regeneron Pharmaceuticals (REGN) to $756 from $753, while maintaining a "Market Perform" rating on the stock. This adjustment reflects a modest change in the analyst's valuation, indicating a continued neutral stance on the company's stock performance. The …

Arcutis Biotherapeutics (NASDAQ:ARQT) Matches Navellier's Growth Playbook With Accelerating Fundamentals

Rallybio Corp (RLYB) sees Balyasny group report 0% ownership in 13G/A

Nektar Therapeutics (NKTR) adds $1.02B cash while posting $85.5M loss

MiNK Therapeutics (NASDAQ:INKT) Stock Rating Lowered by Zacks Research

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Receives Average Recommendation of "Moderate Buy" from Brokerages

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) has received an average "Moderate Buy" recommendation from analysts, with an average 12-month price target of $35.57. The company recently exceeded quarterly earnings and revenue expectations, reporting $0.11 EPS against an anticipated $0.06 and $129.86 million in revenue versus $118.85 …

Nektar: Q2 Earnings Snapshot

The article provides a snapshot of Nektar's Q2 earnings. No specific financial details are available in the provided content, as the main article text was not included.

Stock index futures largely flat after S&P 500 closes at record high

[Wall Street New York stock exchange stock market] alexsl Stock index futures were muted on Friday after the S&P 500 closed at a record high in the previous session. Dow futures (INDU [https://seekingalpha.com/symbol/INDU]) -0.12%, S&P 500 futures (SPX [https://seekingalpha.com/symbol/SPX]) +0.02%, and Nasdaq futures (US100:IND) …

Dimensional Fund Advisors LP Sells 288,067 Shares of Summit Therapeutics PLC $SMMT

Dimensional Fund Advisors LP significantly reduced its stake in Summit Therapeutics PLC by 76.5% in the first quarter, selling over 288,000 shares. Despite this, Summit Therapeutics has seen strong insider buying, with executives acquiring 7.87 million shares worth approximately $103.6 million in the past …

Dimensional Fund Advisors LP Sells 12,867 Shares of Rhythm Pharmaceuticals, Inc. $RYTM

Dimensional Fund Advisors LP reduced its stake in Rhythm Pharmaceuticals, Inc. by 40.2% in the first quarter, selling 12,867 shares and retaining 19,151 shares valued at approximately $1.67 million. Despite the sale, Rhythm Pharmaceuticals reported strong quarterly revenue growth of 46.9% year-over-year and beat …

How Investors Are Reacting To Rhythm Pharmaceuticals (RYTM) UK Orphan Expansion For IMCIVREE In Hypothalamic Obesity

Rhythm Pharmaceuticals received expanded UK MHRA authorization and orphan drug designation for IMCIVREE to treat hypothalamic obesity, broadening its market in the UK. While this strengthens the rare-disease thesis for the drug, the company continues to operate at a significant loss, underscoring ongoing funding …

ADMA|ADMA Biologics Inc|Price:9.410|Chg%:-0.370

This article provides a detailed overview of ADMA Biologics Inc. (ADMA) stock, including its current price, market performance, key financial figures, and analyst ratings. It also offers technical analysis, company profile, ownership breakdown, and related instruments in the pharmaceutical sector.

Bank of America Corp DE Decreases Position in Edgewise Therapeutics, Inc. $EWTX

6 Green Days In A Row: AbCellera Biologics Stock Is Up 85%

AbCellera Biologics (ABCL) stock has surged 85% over six consecutive trading days, reaching a new 52-week high and adding $1.5 billion to its market value. While its revenue growth is strong at 101.3% over the last twelve months, the company faces profitability challenges with …

Ultragenyx Pharmaceutical Inc. Stock 12‑Month Price Target Cut to $52, Implies 97% Upside

Ultragenyx Pharmaceutical Inc.'s average 12-month price target has been slightly reduced to $52 from $52.84 by 18 analysts. This new target implies a potential upside of approximately 97% based on the August 13th closing price. The consensus analyst rating remains a "Buy" from 19 …